Open AccessThis article is
- freely available
Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections†
Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium
† This paper is to be considered as a revised and updated version of the paper published by Férir et al.: Ferir, G.; Kaptein, S.; Neyts, J., De Clercq, E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev. Med. Virol. 2008, 18, 19-34.
* Author to whom correspondence should be addressed.
Received: 9 March 2010; in revised form: 18 May 2010 / Accepted: 25 May 2010 / Published: 31 May 2010
Abstract: While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-α, pegylated interferon-α, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.
Keywords: antiviral therapy; HBV therapy; nucleoside analogs; viral hepatitis
Citations to this Article
Cite This Article
MDPI and ACS Style
De Clercq, E.; Férir, G.; Kaptein, S.; Neyts, J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses 2010, 2, 1279-1305.
De Clercq E, Férir G, Kaptein S, Neyts J. Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses. 2010; 2(6):1279-1305.
De Clercq, Erik; Férir, Geoffrey; Kaptein, Suzanne; Neyts, Johan. 2010. "Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections." Viruses 2, no. 6: 1279-1305.